HighTide Therapeutics, Inc. (HIGHTIDE-B) reported a net loss of RMB 167.27 million for the six months ended 30 June 2026, expanding 46.9% year-on-year, as fair-value losses on investments more than offset a sharp reduction in research spending.
Financial Performance • Other income fell 68.6% to RMB 3.30 million, mainly due to a RMB 4.70 million drop in government grants and a RMB 1.80 million decline in deposit interest. • The company booked a RMB 86.99 million net loss under “other gains and losses,” compared with a RMB 5.22 million gain a year earlier, driven by an RMB 86.23 million fair-value loss on its investment in Apollo Multi-Asset Growth Fund amid market volatility. • Research and development expenses decreased 65.4% to RMB 36.83 million, reflecting a RMB 62.30 million cut in third-party contracting costs. • Administrative expenses more than doubled to RMB 43.50 million, mainly on higher professional service fees. • Finance costs rose 106.3% to RMB 3.26 million owing to higher interest on bank borrowings.
Balance Sheet & Liquidity • Cash and bank balances plus short-term and current-maturity deposits totaled RMB 270.28 million, down 17.1% from year-end 2025 due to operating outflows. • Interest-bearing bank borrowings increased to RMB 145.40 million (RMB 110.00 million at end-2025). Gearing ratio climbed to 82.9% from 30.2%. • Current ratio fell to 3.3 from 5.4 six months earlier.
R&D and Pipeline Progress • Core Product HTD1801 (first-in-class AMPK/NLRP3 modulator): – China’s National Medical Products Administration accepted the New Drug Application for type 2 diabetes mellitus (T2DM) in March 2026 after completion of three Phase III trials. – Phase IIb MASH study and global multi-regional trials completed. – Published positive Phase III combination data with metformin in NEJM Evidence, showing HbA1c reduction of 1.2% at Week 24 and durable benefits to Week 52. • Additional indications under study include chronic kidney disease, obesity, and primary sclerosing cholangitis. • Pipeline comprises five other proprietary candidates (HTD4010, HTF1037, HTF1057, HTD1804, HTD1805) covering eight indications.
Capital Management & Use of Proceeds • Unutilized IPO proceeds stood at HK$9.10 million as of 30 June 2026; remaining balance earmarked for early-stage R&D. • Net proceeds of HK$48.20 million from the July 2025 share placing remain allocated to HTD1801 clinical development and commercialization.
Post-Period Event • On 7 August 2026, the company raised approximately HK$222.40 million via a new share placing, earmarked for HTD1801 commercialization, indication expansion, other pipeline R&D, and general working capital.
Outlook HighTide aims to commercialize HTD1801 for T2DM in China in 2027 while pursuing additional indications and maintaining global clinical programs across its CKM-focused pipeline.